Zacks: Brokerages Anticipate Intra-Cellular Therapies Inc (ITCI) Will Announce Earnings of -$0.89 Per Share
Equities analysts forecast that Intra-Cellular Therapies Inc (NASDAQ:ITCI) will announce earnings of ($0.89) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Intra-Cellular Therapies’ earnings. The highest EPS estimate is ($0.84) and the lowest is ($0.94). Intra-Cellular Therapies posted earnings of ($0.65) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 36.9%. The company is scheduled to report its next earnings report on Thursday, May 2nd.
According to Zacks, analysts expect that Intra-Cellular Therapies will report full-year earnings of ($4.05) per share for the current fiscal year, with EPS estimates ranging from ($4.15) to ($4.00). For the next financial year, analysts forecast that the company will post earnings of ($3.05) per share, with EPS estimates ranging from ($3.75) to ($2.54). Zacks’ EPS averages are an average based on a survey of research firms that that provide coverage for Intra-Cellular Therapies.
Intra-Cellular Therapies (NASDAQ:ITCI) last posted its earnings results on Wednesday, February 27th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.91) by $0.16.
Shares of NASDAQ ITCI traded up $0.08 during trading on Thursday, hitting $13.35. The stock had a trading volume of 292,958 shares, compared to its average volume of 329,643. Intra-Cellular Therapies has a 12 month low of $10.21 and a 12 month high of $25.82. The firm has a market cap of $724.83 million, a price-to-earnings ratio of -4.70 and a beta of 1.41.
In related news, CEO Sharon Mates sold 6,604 shares of the stock in a transaction dated Monday, January 7th. The shares were sold at an average price of $12.43, for a total transaction of $82,087.72. Following the completion of the transaction, the chief executive officer now owns 1,190,909 shares in the company, valued at $14,802,998.87. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Michael Halstead sold 21,458 shares of the stock in a transaction dated Friday, January 4th. The shares were sold at an average price of $11.46, for a total transaction of $245,908.68. Following the transaction, the executive vice president now owns 24,757 shares of the company’s stock, valued at approximately $283,715.22. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 113,209 shares of company stock valued at $1,301,080. 17.40% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Quantbot Technologies LP lifted its holdings in Intra-Cellular Therapies by 5,520.7% during the third quarter. Quantbot Technologies LP now owns 4,609 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 4,527 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in Intra-Cellular Therapies during the fourth quarter valued at about $142,000. Metropolitan Life Insurance Co. NY lifted its holdings in Intra-Cellular Therapies by 354.8% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 14,016 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 10,934 shares during the last quarter. Legal & General Group Plc lifted its holdings in Intra-Cellular Therapies by 9.4% during the fourth quarter. Legal & General Group Plc now owns 16,044 shares of the biopharmaceutical company’s stock valued at $183,000 after purchasing an additional 1,374 shares during the last quarter. Finally, Creative Planning purchased a new stake in Intra-Cellular Therapies during the fourth quarter valued at about $228,000. Institutional investors own 68.68% of the company’s stock.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.